edoc

PXR-mediated induction of human CYP3A4 and mouse Cyp3a11 by the glucocorticoid budesonide

Zimmermann, Christian and van Waterschoot, Robert A. B. and Harmsen, Stefan and Maier, Angelika and Gutmann, Heike and Schinkel, Alfred H.. (2009) PXR-mediated induction of human CYP3A4 and mouse Cyp3a11 by the glucocorticoid budesonide. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, Vol. 36. pp. 565-571.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/dok/A6004123

Downloads: Statistics Overview

Abstract

Budesonide, a glucocorticoid with a high first-pass metabolism, is used for the oral treatment of inflammatory bowel disease. Cytochrome P450 3A4 (CYP3A4) is an enzyme involved in the metabolism of numerous drugs, including budesonide. Since inhibition or induction of CYP3A4 is often the cause of drug-drug interactions we analyzed how budesonide affects the activity and expression of this enzyme. CYP3A4 activity was assessed by the metabolism of a luminogenic substrate (luciferin-benzylether) using recombinant human CYP3A4 protein. We observed no inhibition of the metabolism in the presence of budesonide at concentrations up to 25 microM. Induction experiments in human LS180 colon carcinoma cells showed an increased expression of CYP3A4 mRNA after budesonide treatment. Transactivation assays revealed that budesonide activates the CYP3A4 promoter via the pregnane X receptor (PXR). In mice, oral budesonide administration (25mg/kg) for 4 days induced the murine homolog Cyp3a11 in the intestine 3-fold, whereas liver expression was notably less influenced. In knockout mice devoid of PXR, budesonide-mediated inductions were reduced compared to wild-type mice. In conclusion, we could demonstrate that budesonide is not an efficient inhibitor but rather an inducer of CYP3A via a PXR-mediated mechanism. In vivo, however, oral budesonide administration to mice showed only modest gene induction, which occurred mainly in the intestine. Therefore, the risk for budesonide-mediated drug interactions seems to be low but cannot be ruled out entirely.
Faculties and Departments:03 Faculty of Medicine > Departement Biomedizin > Former Units at DBM > Gastroenterology (Beglinger)
UniBasel Contributors:Gutmann, Heike
Item Type:Article, refereed
Article Subtype:Research Article
Bibsysno:Link to catalogue
Publisher:Elsevier
ISSN:0928-0987
Note:Publication type according to Uni Basel Research Database: Journal article
Last Modified:01 Mar 2013 11:13
Deposited On:01 Mar 2013 11:08

Repository Staff Only: item control page